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Abstract
Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation
and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a
complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability.
Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that
lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer
cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53
pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting
that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and
protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress,
metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53
may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and
synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.
Facts
● Mutant p53 oncoproteins are stabilized and activated in
response to tumor-related stress stimuli.
● Mutant p53 orchestrates stress response mechanisms
that facilitate tumor cell survival and adaptation to
multiple intrinsic and extrinsic stress conditions (geno-
toxic, oxidative, and proteotoxic stress, hostile tumor
microenvironment).
● The stress adaptive processes induced by mutant p53
trigger positive loops feeding its own accumulation in
cancer cells.
● The crosstalk of mutant p53 and stress response
mechanisms discloses therapeutic opportunities for
treating tumors bearing missense TP53 mutations.
Open questions
● Which is the specific contribution of adaptive stress
responses mediated by mutant p53 to the aggressiveness
and mortality of different cancer types?
● Are there additional adaptive responses, yet to be
identified, that can be supported by mutant p53 to
influence cancer cell metabolism, proliferation, and
interaction with the tumor microenvironment?
● To what extent does the crosstalk of mutant p53 and
stress response mechanisms contribute to cancer cell
addiction to mutant p53?
● Could pharmacological inhibition of specific stress
response pathways be used to improve the efficacy of
old and new drugs targeting mutant p53?
Introduction
Tumors evolve through genetic and epigenetic changes that
modify fundamental cellular programs of growth and
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proliferation, followed by selection of reprogrammed cells
that best adapt to a variety of suboptimal or challenging
conditions they encounter, either transiently or durably,
during progression.
The most frequently altered gene in human tumors is
TP53 [1], encoding the p53 protein. TP53 mutations are
associated with adverse prognosis in many sporadic cancers
[1], moreover germline TP53 mutations are causative of the
Li Fraumeni syndrome, a rare familial cancer predisposition
[2]. The primary outcome of TP53 mutations is the loss-of-
wild-type p53 functions, which represents a fundamental
advantage during cancer development by depriving cells of
intrinsic tumor suppressive responses, such as senescence
and apoptosis. At variance with most other tumor sup-
pressor genes however, the majority of TP53 mutations are
missense, producing single residue substitutions within the
protein’s DNA-binding domain. p53 missense mutant pro-
teins (hereafter referred to as “mutp53”) lose the ability to
activate canonical p53 target genes, and some mutants exert
trans-dominant repression over the wild-type counterpart.
Beyond this, cancer cells appear to gain selective advan-
tages by retaining only the mutant form of the p53 protein.
This can be explained by the ability of different p53 mutants
to reshape the tumor cell’s transcriptome and proteome, by
virtue of newly established interactions with transcription
regulators, enzymes and other cellular proteins [3, 4]. On
this basis, specific missense p53 mutants have been reported
to subvert crucial cellular pathways and to foster cancer cell
proliferation and survival, promote invasion, migration,
metastasis, and chemoresistance (reviewed in refs. [5, 6]).
Whereas several mutp53 neomorphic phenotypes con-
tributing to tumor aggressiveness have been described, our
understanding of the mechanisms that determine cellular
addiction to mutp53 expression for cancer maintenance and
progression remains incomplete. Part of the tumor sup-
pressive activities of wild-type p53 involves its capability to
help the cell adapt to and survive mild stress conditions,
including oxidative and metabolic stress [7]. Remarkably,
mutp53 becomes stabilized and activated in response to
tumor-related stress conditions, similar to the wild-type
counterpart (see below). Alongside this notion, evidence is
rising that mutp53 can provide cancer cells with the ability
to cope with challenging conditions originated during
tumorigenesis, including hyperproliferation-related DNA
Fig. 1 Mutant p53 promotes adaptive responses to cancer-related stress conditions to support tumor progression. Cancer cells in a growing tumor
are exposed to multiple intrinsic and extrinsic stress conditions. Oncogenic p53 missense mutant forms (mutp53) can sense multiple stress inputs
(blue), and act as homeostatic factors to induce adaptive mechanisms (red). Oxidative and proteotoxic stress: mutp53 has been shown to induce a
pro-survival response to oxidative stress [45], to facilitate protein folding [69], and to increase proteasome activity [6, 66] in human cancer cell
lines of breast, lung, and pancreatic origin. DNA lesions: mutp53 was shown to inhibit the DNA-damage response (DDR) in humanized mutp53
knock-in (HUPKI) mice [48, 49], to counteract autophagic cell death in breast cancer [25], and to inhibit therapy-induced apoptosis in head and
neck cancer [55]. Altered metabolic requirements: mutp53 has been shown to sustain anabolic growth by enhancing glucose import and promoting
the Warburg effect in mutp53 knock-in mice [34], and to modulate lipid metabolism in human breast cancer cell lines [42]. Hostile tumor
microenvironment: mutp53 has been shown to modulate the extracellular milieu by promoting angiogenesis in breast cancer [73, 74], amplifying
cancer-promoting inflammation in the colon of knock-in mice [79], and inducing a pro-invasive secretome in human lung tumors and derived cell
lines [77]
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damage, oxidative and proteotoxic stress, nutrient fluctua-
tions, physical constraints, stromal cues, and the anti-tumor
immune response [8]. In this review, we propose and dis-
cuss the hypothesis that a major determinant of the cancer
cell’s addiction to mutp53 derives from its ability to sense
cell-intrinsic and extrinsic transformation-related stress
conditions, and coordinate adaptive responses that support
tumor progression (Fig. 1).
Mutant p53 as a sensor of cancer-related
cellular stress
Similar to wild-type p53, mutp53 proteins are intrinsically
unstable, due to proteasome-mediated degradation pro-
moted by the E3 ubiquitin ligases MDM2 and CHIP [9].
However, in tumor tissues mutp53 proteins accumulate to
elevated levels [10] and such stabilization is required for
execution of their multifaceted oncogenic activities. Several
studies clarified that in cancer cells the activity of MDM2
and CHIP towards mutp53 is specifically inhibited due to
stable association of mutp53 with components of the Hsp90
chaperone machinery, a stress-induced system that supports
cancer cell survival by counteracting protein misfolding and
toxic aggregation (reviewed in ref. [11]). The system
includes Hsp90, Hsp70 and other co-chaperones such as
Hsp40/DNAJA1 (Fig. 2). Pharmacological blockade of this
mutp53-stabilizing mechanism (Fig. 4) with inhibitors of
Hsp90 and of its activator HDAC6 has been demonstrated
to elicit mutp53 degradation in vitro and in vivo [9, 12, 13]
and to increase tumor-free survival of mutp53 knock-in
mice [13].
Similar to wild-type p53, whose accumulation and acti-
vation are triggered by transformation-related stimuli, an
array of inputs originated within the altered tumor context
conspire to induce mutp53 protein stabilization and onco-
genic functions. Of note, some of the underlying mechan-
isms are supported by mutp53 itself, as will be detailed
throughout this review.
During oncogenic transformation the Hsp90 system is
frequently hyper-induced, due to activation of the master
transcription factor heat-shock factor-1 (HSF1) in response
to multiple stress conditions [14, 15]. Significantly, high
levels of oxidative stress—a major inducer of HSF1—are
Fig. 2 The stress adaptive processes induced by mutant p53 trigger positive loops feeding its own accumulation in cancer cells. In tumor cells, the
Heat-shock protein (Hsp) chaperone machinery (comprising Hsp90, Hsp70, and Hsp40/DNAJA1) promotes mutp53 stabilization by inhibiting the
ubiquitin ligases MDM2 and CHIP; mutant p53 can further enhance this mechanism by different means. In breast cancer cells, mutp53 was shown
to induce the mevalonate pathway in concert with SREBP [42], thereby producing M5P that promotes interaction of mutp53 with Hsp40/DNAJA1
[44], as well as GGPP that stimulates RhoA activation and cancer cell mechano-responsiveness. In multiple tumor-derived cell lines, mutp53 was
shown to promote RhoA activation also by inducing its positive regulators GEF-H1 [23] and RhoGDI [24]. Mechano-transduction activates the
Hsp90 cofactor HDAC6, and this was shown to boost mutp53 stabilization in breast cancer cell lines and tumor xenografts [19]. Finally, in human
and mouse breast cancer cell lines, mutp53 was shown to directly upregulate Hsp90/Hsp70 expression by stimulating HSF1 activity [14]. Besides
the ubiquitin-proteasome pathway, mutp53 is degraded by autophagy-mediated proteolysis upon glucose deprivation [25]; in breast cancer models,
mutp53 was shown to counteract the autophagic process [25]. Moreover, in various human cancer cell lines and in mutp53 knock-in mice, mutp53
was shown to increase intracellular glucose levels by stimulating RhoA-dependent membrane translocation of the Glut1 transporter [34]. M5P
mevalonate-5-phosphate; GGPP geranylgeranyl-pyrophosphate
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frequently associated with tumor growth and were shown to
cause mutp53 protein stabilization in vivo [16]. Moreover,
mutp53 potentiates transcriptional induction of several heat-
shock proteins by enhancing HSF1 stabilization and acti-
vation and participating into HSF1 transcriptional com-
plexes at Hsp gene promoters [14], thus generating a feed-
forward circuit that sustains mutp53 accumulation (Fig. 2).
The altered mechanical stimuli displayed by tumor tissues
also contribute to cancer-specific accumulation of mutp53.
Cancer-associated fibrosis generates a dense and stiff extra-
cellular matrix (ECM) leading to integrin activation in focal
adhesions and RhoA-induced remodeling of the actin
cytoskeleton, which in turn favors tumor cell survival, pro-
liferation and tumor progression [17]. It has been reported
that mutp53 accumulation, often spatially heterogeneous
within tumor tissues, is mainly observed at fibrotic regions
[18], suggesting that the physical properties of the micro-
environment may locally influence mutp53 stability. We
have recently demonstrated that RhoA activation and actin-
dependent mechano-transduction induced by elevated ECM
stiffness promote activation of Hsp90 by the mechan-
osensitive HDAC6 deacetylase, thus leading to mutp53 st-
abilization [19, 20] (Fig. 2). RhoA is frequently over-
expressed or hyper-activated in tumors [21]. Notably,
mutp53 has been shown to promote RhoA activation [22] by
inducing its positive regulators GEF-H1 [23] and RhoGDI
[24], thereby sustaining aberrant tumor cell mechano-
responsiveness as well as its own mechano-dependent sta-
bilization (Fig. 2). An important implication of these findings
is that preventing membrane recruitment and activation of
RhoA by inhibiting its prenylation can block stroma-tumor
mechanosignalling, providing a valuable approach to inter-
fere with mutp53 stabilization in tumors [19, 20].
Nutrient limitations represent a major point of vulner-
ability of cancer cells. Interestingly, nutrient availability
also appears to be relevant for mutp53 accumulation in
tumors, as reduced glucose levels induce autophagy-
dependent mutp53 proteolysis [25]. Of note, a dietary
regimen of glucose restriction reduced mutp53 accumula-
tion in mutp53(A135V) knock-in mice and reduced growth
of mutp53-expressing tumor xenografts [25].
Multiple cancer-related stress stimuli trigger post-
translational modifications of mutp53 to modulate its pro-
tein stability and interactions (reviewed in ref. [26]). For
instance, constitutive activation of DNA damage checkpoint
and consequent phosphorylation of Ser15 by ataxia-
telangiectasia mutated (ATM) kinase drive stabilization of
mutp53 by shifting the balance between its mono- and poly-
ubiquitination [27]. This is consistent with the evidence that
expression of Ras and Myc oncogenes as well as exposure
to radiation- and chemotherapy-related genotoxic and oxi-
dative stress induce accumulation of mutp53 in vivo [16].
Similarly, acetylation of C-terminal lysines has been shown
to protect mutp53 from autophagy-mediated degradation
[25]. Post-translational modifications of mutp53 also
enhance its oncogenic activities: for instance, C-terminal
phosphorylation by Polo-like kinase-2 (PLK2) was shown
to boost mutp53 ability to promote breast cancer cells’
proliferation and chemoresistance [28]. We found that
stress-induced phosphorylation at Ser/Thr-Pro sites, with
subsequent Pin1-dependent isomerization, enhances the
ability of mutp53 to neutralize p63 anti-metastatic activity
and to induce a gene expression program associated with
breast cancer aggressiveness and poor prognosis [29]. Pin1
has also been implicated in supporting gain-of-function of
the p53-R249S mutant, frequently detected in human
hepatocellular carcinoma (HCC) associated to dietary
exposure to aflatoxin B1 and hepatitis B infection. In HBV-
positive HCC, CDK4-dependent phosphorylation of the
mutated Ser249-Pro250 preludes to Pin1-dependent mod-
ification, resulting in the interaction of p53-R249S with c-
Myc to promote HCC growth [30].
Mutant p53 rewires the cancer cell’s
metabolism
Reprogramming of cell metabolism is a hallmark of cancer,
required to sustain tumor cells’ biosynthetic needs for
continuous growth and proliferation [31]. Moreover, cell
metabolism is a central hub interconnecting the micro-
environment, cell signaling and the epigenetic landscape,
and is therefore crucial for cancer cells to cope with their
changing environment [32]. Not surprisingly, cell metabo-
lism is affected by multiple oncogenic conditions, including
expression of mutp53.
One widespread metabolic adaptation of cancer cells is
represented by increased glucose uptake accompanied by
aerobic glycolysis (known as Warburg effect), which feeds
tumor growth in hypoxic conditions and contributes to
suppress immune surveillance through extracellular acid-
ification [33]. Tumors hence display extremely high glucose
requirements in face of nutrient scarcity and inadequate
vascular supply (Fig. 1). Mutp53 has been reported to
sustain glucose intake and hence the Warburg effect in
tumor cells and knock-in mice, by the ability to induce
membrane translocation of the glucose transporter GLUT1
via activation of the RhoA-ROCK axis [34] (Fig. 2).
Remarkably, by promoting glucose intake in cancer cells,
mutp53 also inhibits its own autophagy-dependent proteo-
lysis, caused by glucose deprivation [25]. In addition, in
response to energy stress mutp53 can induce aerobic gly-
colysis by directly inhibiting AMP-activated protein kinase
(AMPK) [35].
Depending on the specific context, mutp53 can also
promote oxidative phosphorylation, as shown in pre-
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neoplastic thymus and spleen of Li-Fraumeni (LF) mouse
models and in muscles of LF patients [36]. Importantly,
genetic or pharmacologic interference with mitochondrial
respiration improved tumor-free survival in p53H172/+
mice [37], supporting the concept that mutp53-induced
mitochondrial function enables malignant phenotypes. In
contrast to the classic Warburg view, it has become evident
that tumors display a significant degree of metabolic het-
erogeneity, and cancer cells can indeed activate either gly-
colytic or oxidative metabolism under different
environmental conditions [8]. For instance, slowly pro-
liferating tumor cells (e.g. circulating tumor cells) depend on
mitochondrial function for energy metabolism and survival,
rather than on “classic” glycolysis [38]. It is conceivable that
mutp53 may endow cancer cells with metabolic plasticity,
thus favoring their adaptation to metabolic stress and
increasing their metastatic potential. Of note, a mutp53 R72
variant was recently shown to increase metastatic capability
by stimulating mitochondrial function [39].
Many solid tumors undergo alterations of lipid metabo-
lism, which contribute to cancer in multiple ways, e.g. by
providing membrane lipids and supporting signaling path-
ways that promote proliferation and survival, EMT, cancer
stem cells fate determination, and metastatic dissemination
[40, 41]. Synergistic interaction of mutp53 with SREBPs,
master regulators of fatty acids and cholesterol biosynthesis,
leads to transcriptional induction of the mevalonate pathway
(MVP) [42]. The MVP produces sterols and isoprenoids
required for synthesis of membranes and lipid rafts, signal
transduction and protein prenylation [41]. Several oncogenic
outcomes derive from this activity of mutp53, including dis-
mantling of normal mammary tissue architecture to facilitate
tumor invasion [42] and promoting tumor cells’ aberrant
mechano-responsiveness. In particular, MVP activity drives
geranylgeranyl pyrophosphate (GGPP)-dependent RhoA
activation (Fig. 2), which in turn promotes activation of the
YAP/TAZ oncoproteins [43], as well as stabilization of
mutp53 itself [19] (Fig. 2). In addition, induction of
mevalonate-5-phosphate production along the MVP has been
shown to cause mutp53 stabilization by stimulating its inter-
action with the Hsp40/DNAJ chaperone that inhibits mutp53
ubiquitination [44]. All these findings add on to the concept
that, whereas modifying tumor cell’s adaptive processes,
mutp53 induces positive regulatory loops feeding its own
accumulation and oncogenic activities (Fig. 2).
Mutant p53 enhances cancer cell survival
under oxidative and genotoxic stress
conditions
High levels of oxidative stress are frequently encountered
during transformation as a consequence of genetic,
metabolic and microenvironmental alterations, and pre-
venting excess damage due to ROS accumulation is
essential for cancer cytoprotection. The transcription factor
NRF2 is central to control key components of endogenous
antioxidant systems. Very recently, our group demonstrated
that missense mutp53 interacts with NRF2 and contributes
to selectively activating or repressing specific components
of its transcriptional program, thereby promoting a pro-
survival oxidative stress response that allows cancer cells to
cope with high levels of intracellular ROS [45]. The
mutp53-activated NRF2 target gene signature is associated
with poor patient prognosis in breast cancer, and includes
genes with pro-survival function, such as thioredoxin
(TXN); in contrast, mutp53 represses other NRF2 targets
including heme oxygenase 1 (HMOX1), which have been
shown to display cytotoxic effects in cancer cells, although
being cytoprotective in untransformed cells [46].
As a consequence of oxidative stress, DNA hyper-
replication and telomere shortening, tumor cells endure
persistent DNA lesions, leading to chronic activation of the
DNA damage response (DDR), a tumor suppressive barrier
that eliminates incipient cancer cells through either senes-
cence or apoptosis [47]. Moreover, chemotherapy drugs
represent major genotoxic stressors for tumor cells. Mutp53
interferes with DDR induction, by blocking the activation of
the apical stress-sensor kinase ATM via disruption of the
MRE11–RAD50–NSB complex [48, 49]. Loss of ATM
function dampens homologous recombination (HR)-medi-
ated DNA repair, rendering cells dependent on the activity
of the enzyme poly(ADP ribose) polymerase 1 (PARP1).
Interestingly, a proteomic analysis unveiled that
mutp53 stimulates chromatin association and nuclear
activity of PARP1, resulting in increased poly-ADP-
ribosylated targets [50]. It is conceivable that, while
blocking DDR activation on one hand, on the other hand
mutp53 stimulates PARP function as a stress support
mechanism allowing tumor cell survival in face of high
levels of DNA damage. These activities likely underlie also
mutp53-dependent adaptive responses promoting che-
motherapy and radiotherapy resistance in tumor cells.
In addition, p53 mutants have been shown to boost HR-
mediated DNA repair by enhancing topoisomerase 1 (Top1)
function, although this activity has been reported to result in
hyper-recombination and genomic instability [51]. It is also
possible that mutp53 promotes chromatin recruitment of
PARP, along with DNA replication factors PCNA and
MCM4, to increase DNA replication efficiency [50].
Indeed, mutp53 has been recently shown to increase DNA
replication origin firing and to stabilize replication forks,
thus facilitating the proliferation of cells with genomic
abnormalities. Consistently, mutp53 depletion leads to
increased fork collapse in transformed cells [52]. Other
adaptive mechanisms to proliferation-related stress may
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derive from DNA damage-induced association of mutp53
with DNA topoisomerase 2-binding protein 1 (TopBP1)
[53], a scaffold protein that modulates DNA damage
checkpoint, DNA replication and transcription [54]. Finally,
mutp53 promotes cancer cell survival under tumor- and
therapy-associated stress conditions by inhibiting the
apoptotic and autophagic responses. mutp53 has been
shown to promote resistance to chemotherapy in HNSC
cancer by its ability to inhibit the p73 pro-apoptotic tran-
scriptional program [55]; moreover, mutp53 can directly
block caspase 9 activity [56], as well as caspase 9-mediated
activation of mitochondrial caspase 3 [57]. p53 mutants
have been demonstrated to suppress autophagy in tumor
cells by various mechanisms. In particular, mutp53 directly
inhibits the AMPK kinase, that under metabolic stress sti-
mulates autophagy by phosphorylation of several tran-
scription factors and metabolic enzymes, and stimulates the
Akt/mTOR pathways in breast and pacreas cancer cells
[58]. In addition to promoting autophagy resistance through
cytoplasmic activities [59], inhibition of autophagy-related
ATG12 gene by mutp53 has also been reported [58]. Of
note, counteracting autophagy also protects mutp53 from
proteolysis [60] (Fig. 2).
Adaptation to hypoxic conditions is a critical factor for
tumor evolution. The cellular response to hypoxia is mainly
regulated by the hypoxia inducible factor-1 (HIF-1). It has
been reported that tumors bearing TP53 mutations are
generally characterized by higher HIF-1α levels [61], which
can contribute to angiogenesis, chemoresistance, inhibition
of apoptosis, and of autophagy. mutp53 appears to stimulate
HIF-1α stabilization by inducing its dissociation from the
ubiquitin-ligase MDM2 in hypoxic conditions [61]. This is
consistent with the reported ability of mutp53 to inhibit the
anti-metastatic p63 target gene Sharp1 [62], a factor that
promotes ubiquitin-mediated degradation of HIF and blunts
HIF-induced malignant cell behavior.
Mutant p53 facilitates adaptation to
proteotoxic stress
Proteotoxic stress in tumor cells arises as a consequence of
enhanced protein synthesis and of gene mutations, includ-
ing copy number alterations that change the stoichiometry
of protein-complexes, and point mutations giving rise to
aberrant peptides. All these events pose a high burden on
the protein folding and degradation machineries of pro-
liferating cancer cells.
Accumulation of misfolded proteins in the ER activates the
unfolded protein response (UPR), a conserved transcriptional
program that helps resolve protein stress, but can also trigger
apoptosis [63]. Cancer cells must therefore develop mechan-
isms that favor adaptation to protein stress, and limit apoptotic
outcomes of pathways triggered by accumulation of unfolded
proteins. Various experimental evidences suggests that
mutp53 has a role in this process (Fig. 3).
The first such evidence is that mutp53 enhances activity
of the proteasome. Earlier studies reported that mutp53 can
upregulate expression of some proteasome subunits
[50, 64], and of the proteasome activator REGγ [65]. More
recently, in triple-negative breast cancer (TNBC) cell lines,
we established that proteasome upregulation is in fact a
highly conserved feature of oncogenic p53 mutants, corre-
lating with enhanced protein degradation [66]. Mechan-
istically, this depends on the ability of mutp53 to interact
with the transcription factor NRF2, and to selectively sti-
mulate NRF2-dependent upregulation of proteasome sub-
unit genes. The resulting enhanced proteasome activity in
cancer cells bearing mutp53 increases their fitness and
aggressiveness by accelerating the turnover of oncosup-
pressors such as CDK inhibitors or pro-apoptotic proteins,
but also by enhancing resistance to proteotoxic stress. Of
note, an augmented protein degradation capacity, associated
to efficient elimination of misfolded nuclear and cyto-
plasmic proteins, was recently shown to be instrumental for
transformation in various cell models. Strikingly, this
capacity is mediated by NRF2-dependent upregulation of
proteasome subunits and TRIM proteins [67].
Fig. 3 Mutant p53 facilitates adaptation to proteotoxic stress by mul-
tiple mechanisms. a In breast cancer cell lines, it was shown that
mutp53 cooperates with NRF2 to induce expression of multiple pro-
teasome subunits, accelerating turnover of tumor-suppressor proteins
[66]. At the same time, increased proteasome activity contributes to
alleviate stress caused by accumulation of misfolded proteins. b In
pancreatic and breast cancer cell lines, it was shown that mutp53
cooperates with Sp1 to induce expression of ENTPD5, an enzyme
involved in quality control of N-glycosylated secreted and membrane
proteins, enhancing production of growth factors and growth-factor
receptors [69]. At the same time, ENTPD5 may favor protein folding
in the ER, and promote secretion. c Finally, in human and mouse
breast cancer cell lines, it was shown that mutp53 cooperates with
HSF1 to induce expression of various Hsp chaperones, contributing to
alleviate proteotoxic stress, at the same time promoting
mutp53 stabilization [14]
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The second evidence is that mutp53 upregulates Heat-
shock proteins (Hsp). Li et al. [14] reported that mutp53
enhances stabilization and activation of heat-shock factor-1
(HSF1). In turn, mutp53 and HSF1 interact and bind
together the promoters of several heat-shock proteins; thus,
cells with mutp53 not only have increased HSF1 levels/
activity, but also display an amplified transcriptional heat-
shock response. Accordingly, cancer cell lines with mutp53
are more resistant to proteotoxic stress induced by heat
shock, but also by proteasome inhibitors [14]. Moreover,
HSF1-dependent accumulation of Hsps concurs to
mutp53 stabilization in tumor cells [14], disclosing another
feed-forward circuit instigated by mutp53. In addition to
inducing chaperones, HSF1 coordinates a complex tran-
scriptional response that affects cell proliferation, migration/
invasion, and inhibition of apoptosis [68]. Thus, the inter-
action between mutp53 and HSF1 helps cancer cells to cope
with proteotoxic stress on two fronts: by stimulating adap-
tation and by preventing apoptosis.
Finally, recent work associated mutp53 to the folding of
glycoproteins in the ER [69]. This activity involves mutp53-
dependent upregulation of ENTPD5, an enzyme of the
calnexin/calreticulin chaperone system that guides folding
of N-glycosylated proteins [70]. Notably, ENTPD5 deple-
tion blocked invasion of mutp53-bearing cancer cells, while
ENTPD5 overexpression rescued invasion of cancer cells
depleted of endogenous mutp53, suggesting that ENTPD5
is a crucial mediator of mutp53 pro-metastatic gain-of
function [69]. Experiments showed that the mutp53/
ENTPD5 axis is required for maturation of N-glycosylated
proteins and their transfer to Golgi compartment. Data
suggest that maturation and processing of glycoproteins in
the ER is fundamental for mutp53 oncogenic activity; the
pro-tumorigenic effect of this process may be due to
enhanced expression of membrane receptors, but also to
enhanced secretion of extracellular mediators. This obser-
vation provides a first evidence that mutp53 may favor the
folding of secreted and membrane proteins in the endo-
plasmic reticulum, possibly also contributing to alleviate the
cytostatic effects of ER stress (Fig. 3).
Mutant p53 facilitates establishment of a
pro-oncogenic tumor microenvironment
Most tumors grow under a strong selective pressure from
the surrounding environment. In particular during the
invasion-metastasis process, cancer cells face stress condi-
tions such as matrix detachment, interaction with altered
stromal components, shear mechanical forces, and the pre-
sence of an anti-tumor immune response. The ability of
cancer cells to actively shape a permissive microenviron-
ment is thus crucial for cancer progression.
Increasing evidence indicates that mutp53 can remodel
the tumor microenvironment, enhancing cancer cell adap-
tation to hostile extracellular conditions. First of all, mutp53
can stimulate tumor neo-angiogenesis. An old study showed
that mutp53 overexpression induced VEGF in mouse
fibroblasts [71]. Similarly, expression of mutp53 in bone
marrow stromal cells increased production and secretion of
VEGF, supporting the growth of leukemic cells [72].
Indeed, p53 mutation and VEGF levels are significantly
correlated, at least in breast cancer [73]. In addition to
VEGF, mutp53 can also increase cancer angiogenesis by
upregulating ID4, a member of the ID family proteins. In
turn, ID4 enhances post-transcriptionally the expression and
secretion of pro-angiogenic cytokines IL8 and GRO1/
CXCL1, stimulating tumor neo-vascularization [74].
Cancer cells secrete a variety of molecules that foster
tumor growth and reseeding, and reshape the local micro-
environment to facilitate invasion and metastatic dis-
semination. Analysis of mutp53-dependent tumor cell
secretomes has suggested that mutp53-driven oncogenicity
may act via regulating the expression of secreted proteins
that function in either autocrine or paracrine signaling to
induce migration and invasion of tumor cells [75]. Among
these alpha-1 antitrypsin (A1AT) was identified as a critical
effector of mutp53 in driving lung cancer invasion in vitro
and in vivo, and correlated with adverse prognosis in
mutp53-expressing lung adenocarcinoma patients [76].
Another feature of solid tumors is the presence of
abundant inflammatory molecules secreted by cancer cells
and by infiltrating immune cells. Inflammatory mediators
can stimulate cell proliferation and motility, thus driving
tumor aggressiveness; but factors such as TNF-α also
convey powerful growth-restraining and pro-apoptotic sig-
nals. Thus, cancer cells must adapt to chronic inflammation
by cutting the pro-apoptotic circuits, and amplifying the
pro-survival and pro-migratory inputs of inflammatory
signals. In this respect, mutp53 actively reshapes the profile
of cytokines and chemokines secreted by cancer cells,
contributing to establish a homeostatic microenvironment
that eventually supports cancer cell growth and dissemina-
tion. For instance, mutp53 was reported to induce CXCL5,
CXCL8, and CXCL12, correlating with increased cell
migration and invasion, thus confirming that secretion of
pro-angiogenic factors and chemokines is a gain-of-function
of mutp53 [77].
The impact of mutp53 on the inflammatory tumor
microenvironment is largely dependent on a functional
interaction with the transcriptional regulator NF-κB. In fact,
mutp53 was shown to promote p65 RelA nuclear translo-
cation and amplify NF-κB transcriptional activity in cancer
cells treated with TNFα [78–80]. Interestingly, mutp53 can
influence TNF-induced NF-κB activation also by blocking
the tumor suppressor protein DAB2IP, a cytoplasmic
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modulator that normally inhibits NF-κB and promotes TNF-
induced activation of ASK1/JNK [81]. As a consequence,
TNF stimulation of TNBC cells with mutp53 fails to induce
apoptosis, but enhances cell migration and invasion [82].
The action of mutp53 on NF-κB may be particularly
relevant in the context of the inflamed tumor micro-
environment. Indeed, expression of mutp53 dramatically
increased the incidence of invasive colon carcinoma in a
mouse model of chronic colitis [79]. The activation of NF-
κB sustained by mutp53 has two consequences: it amplifies
the inflammatory response, by increased cytokine
production, and it protects the cancer cell from cytotoxic
effects of such microenvironment, by activating pro-
survival pathways.
It appears that p53 mutation can also protect cancer cells
from anti-tumor signals produced by other cell populations
in the microenvironment. For instance, in vitro studies
based on co-culture suggest that mutp53 protects cells from
tumor-suppressive IFN-beta secreted by cancer associated
fibroblasts (CAFs), enhancing survival, proliferation, and
migration of lung carcinoma cell lines [83].
Finally, this concept might be extended even further, as
we observed that a TNBC cell line expressing p53(R280K),
when exposed to TNF, secretes chemokines that modulate
recruitment of immune cells to the tumor [82]. More
recently, it has been shown that mutp53-expressing cancers
reprogram macrophages to a tumor supporting and anti-
inflammatory state via exosomal secretion of miR-1246
[84]. These observations, suggesting that mutp53 could
shape the tumor immune infiltrate, deserve further studies
for their potential clinical implications.
The homeostatic functions of mutp53
disclose therapeutic opportunities for cancer
treatment
There is ample experimental evidence showing that inter-
ference with mutp53 expression or activity by RNAi or
pharmacological approaches leads to decreased cancer cell
proliferation, survival and metastasis, and even causes
tumor regression in vivo (reviewed in refs. [3, 85]). Given
the uniquely high incidence of missense TP53 mutations
across many different tumor types, strategies aimed at
blocking mutp53 would be expected to produce a huge
impact on cancer treatment. However, anticancer therapies
based on directly targeting mutp53 are still far from clinical
practice: to date, the only compound that has successfully
reached phase I/II clinical trials is the small molecule APR-
246 (PRIMA-1MET), which reverts mutp53 to a wild type
like conformation [86]. While doubts remain on whether
mutp53 may in fact represent a tractable target, alternative
therapeutic strategies may be envisaged to exploit tumor
cells’ synthetic lethal interactions and dependencies on
stress support mechanisms deployed by mutp53 (Fig. 4 and
Table 1). These could become treatments of choice for
tumors characterized by high TP53 mutation rate and that
still lack targeted therapeutic options, such as triple negative
breast cancer and ovarian cancer.
For instance, the ability of mutp53 to inhibit autophagy
and promote cell survival by stimulating the mTOR path-
way sensitized mutp53-expressing breast and pancreas
cancer cells to treatment with the mTOR inhibitor Ever-
olimus [58]. Along this line, it has been recently shown that
Fig. 4 A schematic view of therapeutic opportunities targeting mutp53
and the homeostatic mechanisms it coordinates in cancer cells. Cancer
cell addiction to mutp53-dependent stress support mechanisms can be
exploited for therapeutic purposes by implementing pharmacologic
strategies aimed at disrupting the balance of pro- and anti-survival
signaling, in combination with molecules that directly target mutp53
and/or the mechanisms leading to its cancer-specific activation.
PRIMA-1 is paradigmatic of small molecule compounds restoring
mutp53 to its wild-type conformation and leading to its degradation.
Destabilization of mutp53 by inhibition of the Heat-shock protein
(Hsp) chaperone machinery can be obtained by different compounds,
including inhibitors of Hsp90-Hsp40 and HDAC inhibitors (SAHA).
Molecules inhibiting different steps of the Mevalonate-RhoA axis,
including statins, Zoledronic Acid (ZA) and geranylgeranyl-
transferase inhibitors (GGTI) can indirectly block Hsp90 activation
and mutp53 stabilization, also blunting other oncogenic effects of this
metabolic axis. Similarly, Pin1 inhibitors such as ATRA/ATO and
KPT-6566 prevent mutp53 oncogenic activation in tumor cells. Met-
formin could block glucose-dependent mutp53 stabilization, and
mTOR inibitors such as Everolimus curb tumor cell survival. Ther-
apeutic approaches can be aimed to inhibit the stress support pathways
sustained by mutp53 (sensitization), or to exacerbate stress conditions
to overcome stress support pathways (stress overload). E.g. protea-
some inhibitors blunt a major proteotoxic stress response pathway;
inhibitors of the thioredoxin system (e.g. Auranofin) block antioxidant
mechanisms; DDR kinase inhibitors and PARP inhibitors prevent
responses to genotoxic stress; PRIMA-1 and the Pin1 inhibitor KPT-
6566 increase ROS levels in cancer cells
F. Mantovani et al.
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Mutant p53 as a guardian of the cancer cell
pharmacological activation of RAR-γ with a synthetic
retinoid could circumvent resistance to p53 restoration in
mutp53-bearing lymphomas [87].
Synthetic lethality of missense TP53 mutations with
blockade of DNA damage response and DNA repair path-
ways could be exploited to sensitize mutp53-expressing
cells to chemotherapy. It has been shown that mutp53-
bearing cancer cells are dependent on nuclear PARP activity
for survival, and display increased sensitivity to treatment
with the PARP inhibitor Rucaparib as compared to wild-
type p53 cells [50]. Also, the PF477736 small molecule
inhibitor of checkpoint kinase Chk1, which is induced by
mutp53 to prevent collapse of DNA replication forks and
lethal genome rearrangements, reduced the growth of lung
cancer xenografts in mice in a mutp53-dependent manner
[52].
The mutp53/NRF2 axis, enabling cancer cells to cope
with high levels of intracellular ROS, also discloses impli-
cations for cancer treatment. In fact, loss-of-mutp53 impairs
the activation of antioxidant systems, sensitizing cancer
cells to cell death induced by excessive oxidative damage
[45]. Interestingly, APR-246 PRIMA-1MET has been
reported to increase ROS levels in cancer cells by targeting
Thioredoxin reductase 1, independently of its action on
mutp53 [88]. In fact, combined treatment with PRIMA-
1MET and the FDA-approved compound Auranofin (inhi-
bitor of the thioredoxin system) synergized in inducing
cytotoxicity of breast cancer cells [45].
Similarly, mutp53 inhibition may sensitize tumors to
proteotoxic stress. Tumor cells rely on the ubiquitin-
proteasome pathway to reduce formation of toxic aggre-
gates of misfolded proteins, and treatment with proteasome
inhibitors has proven effective in malignancies, such as
multiple myeloma and mantle cell lymphoma [89, 90]. As
mentioned above, mutp53 protects cancer cells from pro-
teotoxic stress by enhancing the expression of proteasome
genes, which also confers resistance to proteasome inhibi-
tors [66]. Treatment of mice with a combination of Carfil-
zomib and PRIMA-1MET reduced growth of breast cancer
xenografts in a mutp53-dependent fashion [66]. Thus,
clinical studies combining inhibition of mutp53 and pro-
teasome activity may be hopefully envisioned in a near
future. As mutp53 induces accumulation of Hsps, that in
turn concur to mutp53 stabilization in tumor cells [14],
treatment with Hsp inhibitors should induce mutp53
destabilization and concomitant sensitization of tumor
cells to proteotoxic stress. Indeed, blocking Hsp90
activity with new generation inhibitors such as Ganetespib
and the Geldanamycin derivative 17-DMAG, as well as the
HDAC inhibitor Vorinostat (SAHA), restrained growth of
mutp53-expressing tumors in vivo [13]. Supporting the
clinical efficacy of this strategy, the Hsp90 inhibitor
AUY922 was found to synergize with CCPT (concurrent
cisplatin radiotherapy) in HNSCC cancers with mutant
TP53 [91].
Tumor associated metabolic reprogramming introduces
metabolic liabilities that can be exploited for precision
anticancer treatments [92]. For instance, the dependency of
tumor cells on mutp53-induced glucose intake may be tar-
geted to generate metabolic stress overload. Administration
of glucose-lowering drugs, such as the anti-diabetic com-
pound Metformin, could be effective also in that it inter-
rupts the vicious circle whereby mutp53 stimulates glucose
supply and sustains its own stabilization in tumor cells [25].
In fact, glucose restriction was shown to inhibit mutp53
accumulation in p53(A135V) knock-in mice, and to reduce
growth of mutp53-expressing tumor xenografts [25],
whereas Metformin treatment increased tumor-free survival
in mutp53 R172H knock-in mice [37].
A similar reasoning can be applied to the MVP, whose
induction both mediates tumorigenic activities of mutp53
and supports its accumulation in cancer cells [19, 44].
Indeed, blocking the MVP flux with statins [42, 44, 93], or
preventing RhoA geranyl-geranylation by treatment with
zoledronic acid (ZA) or inhibitors of protein geranylger-
anyltransferase type I, such as GGTI-298 [19], effectively
reduced mutp53 accumulation in cancer cells and dampened
mutp53-dependent malignant phenotypes. Accordingly,
administration of the clinically approved drugs Atorvastatin
or ZA reduced growth of mutp53-expressing tumor xeno-
grafts in vivo [19, 44].
Finally, alternative pharmacological approaches may
entail targeting druggable components of transduction cas-
cades that convey tumor-related stress signals to mutp53.
An example is blunting phosphorylation-dependent prolyl-
isomerization of mutp53 catalyzed by Pin1, an enzyme
frequently over-expressed in cancers [94]. For instance,
HCC cells expressing mutp53(R249S) appeared to be
highly sensitive to treatment with a CDK4 inhibitor that
blunted Pin1-dependent activation of this particular p53
mutant [30]. While no specific Pin1 inhibitor has yet
reached clinical trials, it has been discovered that All-trans
Retinoic Acid (ATRA) and Arsenic Trioxide (ATO), used
for treatment of acute promyelocytic leukemia, directly
interact with the Pin1 active site, leading to inhibition and
degradation of Pin1 in tumor cells, and to blockade of
several Pin1-dependent cancer-driving pathways [95, 96].
ATO and ATRA synergyzed to inhibit growth of TNBC
cells in vitro and of patient-derived orthotopic xenografts in
mice [96]. However, ATRA has shown moderate efficacy
against solid tumors in clinical trials [97], thus more
effective Pin1 inhibitors are needed. We have recently
isolated a novel Pin1 inhibitor named KPT-6566, able to
covalently bind Pin1 and induce its degradation. This
compound was shown to curb mutp53 GOF activities and
decrease viability of mutp53-expressing cancer cell lines, as
F. Mantovani et al.
well as growth of lung metastasis of mutp53-expressing
TNBC cells [98]. Remarkably, interaction of KPT-6566
with the Pin1 catalytic site releases a quinone-mimicking
drug that generates reactive oxygen species, thus combining
Pin1/mutp53 inhibition with oxidative stress overload in
cancer cells.
Concluding remarks
The stress phenotypes associated to tumorigenesis have
been proposed to represent a common hallmark of cancer,
and several oncogenic and non-oncogenic pathways were
shown to generate adaptive responses that are essential for
cancer cell survival [99]. Importantly, these pathways can
be exploited to selectively kill cancer cells, through either
stress sensitization or stress overload, with minor effects
on normal cells. A wide array of neomorphic activities
contributing to cancer progression has been attributed to
missense p53 mutants: understanding the functions that
generate tumor cell addiction in specific contexts is of
primary interest to elaborate effective anticancer strate-
gies. Here we have examined the abilities of mutp53 to
support cancer cell survival under harsh conditions: these
mirror basal functions of the wild-type counterpart,
although being fulfilled through distinct mechanisms. We
have hypothesized that these adaptive mechanisms may
represent a major determinant of mutp53 oncogenic
activity. Thus, mutp53-activated stress response pathways
may be targeted to specifically sensitize, or overload,
cancer cells bearing oncogenic p53 mutations to stress-
inducing treatments. In other words, anticancer therapies
based on drug combinations that either directly or indir-
ectly hit mutp53-dependent homeostatic circuits can be
expected to provide a number of exciting therapeutic
possibilities (Table 1).
Clearly, the variety of TP53 missense mutations pro-
duces distinct functional consequences, thus tumor vulner-
abilities may differ based on the specific TP53 mutation, as
well as on the tumor type. Moreover, how the diversity of
p53 isoforms reflects into oncogenic activities of mutp53 is
presently a black box. Much study is still required to define
these aspects, and we anticipate that multi-mutant, multi-
omic approaches could provide a clearer perspective on the
range of mutp53 cancer-protecting activities, and their
prevalence in different mutp53 variants and in different
tumor contexts, helping to identify “core” mutp53 activities
as ideal therapeutic targets.
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